Showing results (571-580 of 1,409) with videos related to

Sort By:
Pageof 141
Oncogene|October 7, 2014
Differential roles of STAT3 in the initiation and growth of lung cancerJingjiao Zhou, Zhaoxia Qu, Shapei Yan, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical proceduresA D Shapiro, G C White Ii, H C Kim, et al.
American Journal of Respiratory Cell and Molecular Biology|June 11, 2014
Macrophage elastase suppresses white adipose tissue expansion with cigarette smokingTakao Tsuji, Neil J Kelly, Saeko Takahashi, et al.
Current Treatment Options in Cardiovascular Medicine|June 21, 2015
Role of Computed Tomography in Assessment of the Thoracic AortaNandini M Meyersohn, Khristine Ghemigian, Michael D Shapiro, et al.
Journal of Managed Care & Specialty Pharmacy|February 4, 2026
Real-world adherence to and persistence with emicizumab in people with hemophilia A using a national claims databaseJanet S Lee, Robert Schuldt, Zhiyu Xia, et al.
Research and Practice in Thrombosis and Haemostasis|September 11, 2023
Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasisAmy D Shapiro, Hervé Chambost, Margareth C Ozelo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 6, 2007
CD8+ T Cells are required for inflammation and destruction in cigarette smoke-induced emphysema in miceToshitaka Maeno, A McGarry Houghton, Pablo A Quintero, et al.
Science (New York, N.Y.)|January 7, 1998
NDR1, a pathogen-induced component required for Arabidopsis disease resistanceK S Century, A D Shapiro, P P Repetti, et al.
Vector Borne and Zoonotic Diseases (Larchmont, N.Y.)|May 25, 2012
Critical analysis of treatment trials of rhesus macaques infected with Borrelia burgdorferi reveals important flaws in experimental designGary P Wormser, Phillip J Baker, Susan O'Connell, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 21, 2013
Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registriesA D Shapiro, E J Neufeld, V Blanchette, et al.
Pageof 141